Baseline characteristics of patients who were not transfusion independent, by treatment arm
| Characteristic . | Pacritinib n = 41 . | BAT n = 43 . |
|---|---|---|
| Age in y, median (range) | 67 (49-85) | 70 (50-83) |
| Female, n (%) | 16 (39%) | 17 (40%) |
| Primary MF, n (%) | 34 (83%) | 27 (63%) |
| DIPSS high risk, n (%) | 18 (44%) | 19 (44%) |
| Time since MF diagnosis in years, median | 2.5 | 2.9 |
| Prior JAK2 inhibitor, n (%) | 23 (56%) | 25 (58%) |
| Bone marrow fibrosis grade 3, n (%) | 26 (63%) | 25 (58%) |
| Platelet count (×109/L), median (IQR) | 41 (21-70) | 43 (23-67) |
| Platelet count <50 × 109/L, n (%) | 25 (61%) | 26 (61%) |
| Hemoglobin (g/dL), median (IQR) | 8.7 (7.7-9.7) | 8.6 (7.7-9.4) |
| RBC transfusions per month within 90 days before informed consent, median (IQR) | 1.5 (0.8-3.4) | 1.9 (1.0-3.7) |
| White blood cells (×109/L), median (IQR) | 5.4 (3.4-18.1) | 5.1 (3.5-13.7) |
| JAK2V617F mutation | 35 | 34 |
| Allele burden <50% | 26 (74%) | 25 (74%) |
| Characteristic . | Pacritinib n = 41 . | BAT n = 43 . |
|---|---|---|
| Age in y, median (range) | 67 (49-85) | 70 (50-83) |
| Female, n (%) | 16 (39%) | 17 (40%) |
| Primary MF, n (%) | 34 (83%) | 27 (63%) |
| DIPSS high risk, n (%) | 18 (44%) | 19 (44%) |
| Time since MF diagnosis in years, median | 2.5 | 2.9 |
| Prior JAK2 inhibitor, n (%) | 23 (56%) | 25 (58%) |
| Bone marrow fibrosis grade 3, n (%) | 26 (63%) | 25 (58%) |
| Platelet count (×109/L), median (IQR) | 41 (21-70) | 43 (23-67) |
| Platelet count <50 × 109/L, n (%) | 25 (61%) | 26 (61%) |
| Hemoglobin (g/dL), median (IQR) | 8.7 (7.7-9.7) | 8.6 (7.7-9.4) |
| RBC transfusions per month within 90 days before informed consent, median (IQR) | 1.5 (0.8-3.4) | 1.9 (1.0-3.7) |
| White blood cells (×109/L), median (IQR) | 5.4 (3.4-18.1) | 5.1 (3.5-13.7) |
| JAK2V617F mutation | 35 | 34 |
| Allele burden <50% | 26 (74%) | 25 (74%) |
Patients randomized to pacritinib 200 mg BID or BAT were included if they had received RBC transfusion in the 12 weeks before treatment. Transfusion independence is based on Gale criteria.
Abbreviations: BAT, best available therapy; BID, twice per day; DIPSS, Dynamic International Prognostic Scoring System; JAK2, Janus associated kinase 2; IQR, interquartile range; MF, myelofibrosis; RBC, red blood cell.Note: Transfusion independence is based on Gale criteria.